Comorbidities in ADHD children treated with methylphenidate: a database study.

Kraut, Angela A; Langner, Ingo; Lindemann, Christina; Banaschewski, Tobias; Petermann, Ulrike; Petermann, Franz; Mikolajczyk, Rafael; Garbe, Edeltraut

Name:

Kraut et al_final.pdf

Size:

346.9Kb

Format:

PDF

Description:

Open Access publication

Download

Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item. When enough users have cast their vote on this item, the average rating will also be shown.

Star rating

Your vote was cast
Thank you for your feedback

Authors

Kraut, Angela A
Langner, Ingo
Lindemann, Christina
Banaschewski, Tobias
Petermann, Ulrike
Petermann, Franz
Mikolajczyk, Rafael
Garbe, Edeltraut

Issue Date

2013

Metadata

Show full item record

Abstract

Methylphenidate (MPH) is the most common drug treatment of attention deficit / hyperactivity disorder (ADHD) in children. Treatment with MPH is contraindicated in the presence of certain psychiatric, cerebro- and cardiovascular conditions. We assessed MPH treatment prevalence and incidence and the frequency of comorbid conditions related to these contraindications in new MPH users compared to a control group without ADHD and ADHD medication.

Citation

Comorbidities in ADHD children treated with methylphenidate: a database study. 2013, 13:11 BMC Psychiatry

Affiliation

Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.

Type

Article

Language

ISSN

1471-244X

Collections

Publications of the AG (ESME)

The following license files are associated with this item: